Navigation Links
Epizyme, Inc. Reports Second Quarter 2013 Financial Results
Date:7/31/2013

Net loss was $2.2 million for the second quarter of 2013 and $9.7 million for the six months ended June 30, 2013, compared to net income of $4.9 million and net loss of $0.6 million for the comparable periods in 2012. The 2012 second quarter net income was largely driven by the revenue recognition of a portion of the $68.0 million upfront payment received from Celgene in April 2012.
  • End of Year Cash Guidance Epizyme expects that its cash and cash equivalents will be approximately $115 million as of December 31, 2013, which it believes will fund the Company until at least mid-2015. Full-year 2013 net cash used in operating activities is expected to be approximately $65 million.
  • Upcoming Milestones

  • EPZ-5676 In the second half of 2013, Epizyme plans to complete the dose escalation stage of the Phase 1 study and initiate the expansion cohort, which will be limited to patients with MLL-r and which may provide an initial assessment of therapeutic effect.
  • EPZ-6438 In 2014, Epizyme plans to initiate the Phase 2 portion of the Phase 1/2 study of EPZ-6438, which will be limited to patients with point mutations in EZH2 and which may provide an initial assessment of therapeutic effect.
  • Conference Call InformationEpizyme will host a conference call and live audio webcast today at 4:30 p.m. EDT to discuss the quarter and provide a corporate update. To participate in the conference call, please dial 1-877-844-6886 (domestic) or 1-970-315-0315 (international) and refer to conference ID 17477005. The live webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com

    The archived webcast will be available on the Company's website beginning approximately two hours after the event.

    About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients w
    '/>"/>

    SOURCE Epizyme, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. China Medical Flat Panel Detector Market & Pressure Injector 2013 Research Reports Now Available at ReportsnReports.com
    2. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
    3. Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope
    4. China Radiotherapy Simulator Market & Digital Radiography 2013 Research Reports Now Available at ReportsnReports.com
    5. Neurocrine Biosciences Reports Second Quarter 2013 Results
    6. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
    7. Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
    8. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
    9. Cepheid Reports 2013 Second Quarter Results
    10. Quest Diagnostics Reports Second Quarter 2013 Financial Results
    11. Global GIS Market in the Retail Industry to 2016: Industry Analysis, Growth, Strategy, Size, Shares, Trend and Forecast Research Report Available at MarketResearchReports
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/28/2015)... (PRWEB) May 28, 2015 DryLet, ... use in applications such as animal waste reduction, ... oil reduction in wastewater treatment plants and restaurant ... the World Pork Expo, June 3-5 in Des ... year in a Wall Street Journal article because ...
    (Date:5/28/2015)... May 28, 2015  PDS Biotechnology Corp. announces ... treatment targeting HPV-16, has generated strong T-cell responses ... pre-cervical cancer is treated by surgical removal of ... effective non-surgical alternative. Results show that it primes ... recognize, target, and kill precancerous and cancerous cells ...
    (Date:5/28/2015)... May 28, 2015 Biscayne Pharmaceuticals, Inc ... of its growth hormone-releasing hormone (GHRH) technology will be discussed ... ASCO Annual Meeting. The data show that the family ... GHRH blockers, is present on many primary breast cancer ... that GHRH antagonists could have broad anti-cancer potential in ...
    (Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
    Breaking Biology Technology:DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
    ... Calif. The University of California, Riverside has received ... of computing that is beyond the scope of conventional ... is to speed up applications that process large amounts ... image recognition. The money is awarded to UC ...
    ... Calif., Oct. 5, 2011 SRI International has been ... totaling $14.3 million. The contracts provide SRI up to ... million for pharmacology and pharmacokinetics studies that will be ... These five-year contracts extend SRI,s preclinical studies for ...
    ... announced the receipt of a two-year $2.8 million grant ... range of charitable, educational and scientific activities through 2013 ... in the life sciences. "As BioCrossroads ... that Lilly Endowment,s significant investment in our initiative has ...
    Cached Biology Technology:Physicists to develop new way of electronic computing 2SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts 2SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts 3Two-year $2.8 million Grant from Lilly Endowment Fuels BioCrossroads' Charitable, Educational and Scientific Mission 2Two-year $2.8 million Grant from Lilly Endowment Fuels BioCrossroads' Charitable, Educational and Scientific Mission 3
    (Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
    (Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... shipping to pre-order customers the first week of May, ... the month of May. Gino ... significant milestone for the company as Wocket® enters the ...
    (Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
    Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
    ... While we grapple with the impact of climate change, archaeologists ... to cope with the last ice age. "The period ... is the most significant climatic event ever faced by humans ... University in Cairns said. Research recently published in ...
    ... by JPMorgan Chase & Co. (NYSE: JPM) and the ... time, allow individual and institutional investors the opportunity to ... to save millions of lives in low-income countries. ... of investors including anchor support from Grand Challenges ...
    ... The results of the new study imply that it is ... sweet flavours. Our pleasure in consuming sweet solutions is driven ... provides: greater reward in the brain is attributed to sugars ... led the study at Yale University School of Medicine USA, ...
    Cached Biology News:Climate change nothing new in Oz 2New investment fund will advance late-stage vaccines, other global health technologies 2New investment fund will advance late-stage vaccines, other global health technologies 3New investment fund will advance late-stage vaccines, other global health technologies 4The brain cannot be fooled by artificial sweeteners 2
    Anti-Conjugated Quinaldic Acid...
    ... stain kits are optimized for use ... Dodeca stainers. This silver stain kit ... in polyacrylamide gels and are mass ... concentrate, silver reagent concentrate, background reducer ...
    The AVR9-8 stream-select valve is a 9-port, 8-position valve for use with the BioLogic DuoFlow system. This valve is used for high-pressure stream selection....
    ... Miscellaneous: Versatile stain for staining RNA (bluish-purple), DNA (blue), ... TLC ≥ 90 % Cation traces: Ca ≤ ... mg/kg Cr ≤ 5 mg/kg Cu ≤ 5 mg/kg ... ≤ 5 mg/kg Mn ≤ 5 mg/kg Na ≤ ...
    Biology Products: